5. CONFLICT OF INTEREST
All members of the EAU Urological Infections Guidelines Panel have provided disclosure statements on all relationships that they have that might be perceived to be a potential source of a conflict of interest. This information in provided below and is also publicly accessible through the EAU website: https://uroweb.org/guidelines/urological-infections. These Guidelines were developed with the financial support of the EAU. No external sources of funding and support have been involved. The EAU is a non-profit organisation, and funding is limited to administrative assistance, travel and meeting expenses. No honoraria or other reimbursements have been provided.
Disclosures: The EAU Guidelines Office certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g. employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following:
G. Bonkat reported receiving company honoraria from Bionorica SE, IBSA, OM Pharma SA, Sun Pharmaceutical Industries (Europe) B.V., Zambon SpA and Hoechst Marion Roussel; fellowship and travel grants from Bionorica SE, OM Pharma SA, Sun Pharmaceutical Industries (Europe) B.V. and IBSA; and being a company consultant for IBSA, OM Pharma SA, Zambon SpA, Sun Pharma and Janssen-Cilag AG. S.E. Geerlings reported being a company consultant for Immontek.
J. Kranz reported receiving company honoraria from Apogepha, Bionorica SE, GSK, Johnson & Johnson, medac GmbH, MSD, OM-Pharma, Repha GmbH and Sysmex; being a company consultant for Bionorica SE, Eumedica, GSK, Johnson & Johnson, medac GmbH, OM-Pharma, Repha GmbH, Shionogi and Sysmex; and receiving research funding from the German Research Foundation (DFG) and LEO Pharma.
J. Medina-Palo reported receiving company speaker honorarium from Boston Scientific SA, GSK, Astellas and Q-Pharma.
L. Schneidewind reported receiving fellowship and travel grants from Apogepha Arzneimittel GmbH and Debiopharma; receiving company speaker honorarium from Bionorica SE; being a company consultant Bristol Myers Squibb, GSK, and MSD Pharma; being the receipt of grants/research supports from DFG, Monika-Kutzner Foundation and DFIT e. V.; and being a member of the German AWMF S3 Guidelines.
S. Schubert reported being the receipt of honoraria or consultation fees from OM Pharma; and being a company consultant for Janssen.
M. Vallée reported participation in a company sponsored speaker’s bureau of IBSA Pharma SAS, Eumedica, GSK and OM Pharma.
F.M.E. Wagenlehner reported being a company consultant for Achaogen, Bionorica, GSK, Janssen, Klosterfrau, Pfizer, MIP Pharma, Shionogi, Spero, VenatorRX and OM-Pharma; receiving company speaker honorarium from Astellas, AstraZeneca, Bionorica, GSK, Janssen, Klosterfrau, MSD, Pfizer, MIP Pharma and OM-Pharma; trial participation for GSK, Klosterfrau, Select Immune, Janssen and VenatoRx; and receipt of grants/research supports from DFG and DZIF.
K. Bausch reported receiving company honoraria from IBSA.
F.P. Stangle reported receiving fellowship and travel grants from Janssen-Cilag Switzerland, and OM-Pharma; being a receipt of grants/research supports from Repha Pharm; and receiving company speaker honorarium from OM-Pharma
T, Cai, B. Köves, G. Mantica, A. Pilatz, R. Veeratterapillay, M. Lambregts, W. Devlies and L. Leitner have nothing to declare.